Facet Biotech - Pipeline - Daclizumab

Abbott Investor Relations
Abbott Careers
Contact

We imagine a day where patients will benefit from more humane cancer treatments

Overview
Daclizumab
Elotuzumab (HuLuc63)
TRU-016
Volociximab (M200)
PDL192

Pipeline Daclizumab

Phase 3 Study in Multiple Sclerosis
Proposed Mechanism of Action

CHOICE Presentation

Facet Biotech - Pipeline - TRU-016

Abbott Investor Relations
Abbott Careers
Contact

We imagine a day where patients will benefit from more humane cancer treatments

Overview
Daclizumab
Elotuzumab (HuLuc63)
TRU-016
Volociximab (M200)
PDL192

Pipeline TRU-016-1

Phase 1 Study in Chronic Lymphocytic Leukemia
Preclinical Study in Non-Hodgkin’s Lymphoma
Preclinical Study in AIID
Publications
Facet Biotech - Pipeline - PDL192

Abbott Investor Relations
Abbott Careers
Contact

We imagine a day where patients will benefit from more humane cancer treatments

Overview
Daclizumab
Elotuzumab (HuLuc63)
TRU-016
Volociximab (M200)
PDL192

Pipeline Pdl192

Publications
Proposed Mechanism of Action
Facet Biotech - Pipeline - Volociximab (M200)

Abbott Investor Relations
Abbott Careers
Contact

We imagine a day where patients will benefit from more humane cancer treatments

Overview
Daclizumab
Elotuzumab (HuLuc63)
TRU-016
Volociximab (M200)
PDL192

Pipeline Voloximab

Publications
Proposed Mechanism of Action
Facet Biotech - Pipeline - Elotuzumab (HuLuc63)

Abbott Investor Relations
Abbott Careers
Contact

We imagine a day where patients will benefit from more humane cancer treatments

Overview
Daclizumab
Elotuzumab (HuLuc63)
TRU-016
Volociximab (M200)
PDL192

Pipeline Elotuzumab

Phase 2 Studies in Multiple Myeloma
Publications
Video about Elotuzumab
Proposed Mechanism of Action